27/11/2014 19:47:21 Free Membership Login

Global Biosimilars Market - Products, Applications and Regulations

Date : 11/29/2012 @ 8:58PM
Source : PR Newswire (US)

Global Biosimilars Market - Products, Applications and Regulations

Global Biosimilars Market - Products, Applications and Regulations

NEW YORK, Nov. 29, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Biosimilars Market - Products, Applications and Regulations

http://www.reportlinker.com/p01048204/Global-Biosimilars-Market---Products-Applications-and-Regulations.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Generic_Drug

Several of the leading 25 manufacturers of biosimilars have been entrenched in the market, and have the experience of marketing products for the last 5-10 years. On the other hand, several companies' position is expected to be challenged over the next ten years, since the rapid growth forecast for the biosimilars market has attracted several new companies to enter this lucrative arena. Current leaders, in order to maintain market share, need to introduce new biosimilars over the next few years with a specific focus on the products in demand. Licensing deals are expected to expand the pipelines of established players, as well as new market entrants.

The global biosimilar market, estimated at US$2 billion in 2012 and expected to touch US$2.7 billion in 2013, is further projected to reach US$19.4 billion by 2018, exhibiting a CAGR of 36.6% over 2009-2018. This growth can be attributed to some of the top-selling biologics coming off-patent over the coming few years and biosimilar manufacturers are bound to make a beeline towards this lucrative opportunity.This report reviews, analyzes and projects the biosimilars market for global and regional markets including the United States, Europe, Asia-Pacific and Rest of World. The market numbers illustrated in this report only represent the market exclusively for the product segments and application areas enunciated above. The regional markets further analyzed for 8 more independent countries across EuropeFrance, Germany, Italy, Spain, the United Kingdom and Rest of Europe; Asia-PacificChina, India, South Korea and Rest of Asia-Pacific.

The market for application areas of biosimilars analyzed in this study includes Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Others. The report also encompasses the market analysis for product segments – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Others.

This 354 page global market report includes 149 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of the market. The statistical tables represent the data for the global market by geographic region, application area and product segment.The report covers the brief business profiles of 43 key global players and 54 major players across the United States – 13; Europe – 18; Asia-Pacific – 19 and Rest of World – 4. The report also provides the listing of the companies engaged in research and development, manufacturing, processing, supplies and distribution of biosimilars. Also enlisting the academic institutions and industry associations engaged in biosimilars, the global list covers the addresses, contact numbers and the website addresses of 168 companies.

TABLE OF CONTENTS:

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION

1.1 mAbs - All The Rage In Biosimilars' New Wave

1.2 The Buildup to the Biosimilar Industry

1.3 Current Players: A Sneak Preview

1.3.1 Celltrion

1.3.2 Gedeon Richter

1.3.3 Biocon

1.4 The Big Pharma Industry: Not One to be Left Out

1.4.1 Baxter-Momenta

1.4.2 Merck Serono-Dr. Reddy's Laboratories

1.4.3 Daiichi Sankyo-Coherus Biosciences

1.4.4 Amgen-Watson

1.4.5 Samsung Biologics-Biogen Idec

1.5 On the Flip Side

1.6 The Winner Takes It All

1.7 Product Outline

1.7.1 What are Biosimilars?

1.7.2 The Process of Approval

1.7.3 Backdrop

1.7.4 The Biologics Price Competition and Innovation Act

1.7.4.1 Data Exclusivity

1.7.5 Biosimilars by Product Type

1.7.5.1 Monoclonal Antibodies

1.7.5.1.1 Production Process

1.7.5.2 Erythropoietin

1.7.5.2.1 Functions of EPO

1.7.5.2.2 Mechanism of Action

1.7.5.2.3 Synthesis and Regulation

1.7.5.2.4 Uses in Medicine

1.7.5.3 Human Growth Hormone

1.7.5.3.1 Recombinant Human Growth Hormone

1.7.5.3.2 Managing Growth Disorders Using Recombinant Human Growth Hormone Biosimilars

1.7.5.4 Insulin

1.7.5.4.1 Biosimilar Insulin

1.7.5.4.2 The Complexity in Producing Biosimilar Insulin

1.7.5.4.3 Biosimilars and the Regulatory Environment Surrounding Them

1.7.5.4.4 The Market for Insulin Biosimilars

1.7.5.5 Granulocyte Colony-Stimulating Factor

1.7.5.5.1 Biological Function

1.7.5.5.2 Genetics

1.7.5.5.3 Use in Therapeutics

1.7.5.6 Interferons

1.7.5.6.1 Interferon Categorization

1.7.5.6.2 Functions of Interferons

1.7.5.6.3 Interferon Alfa

1.7.5.6.4 Interferon Beta-1a

1.7.5.6.5 Interferon Gamma

1.7.5.7 Other Biosimilars

2. BIOSIMILAR APPLICATIONS – A SNAPSHOT

2.1 Blood Disorders

2.2 Chronic and Autoimmune Diseases

2.3 Growth Hormone Deficiency

2.3.1 Growth Hormone Deficiency in Children

2.4 Oncology

2.4.1 Biosimilars in Oncology and Hematology

2.4.2 Biosimilar G-CSF

3. REGULATORY LANDSCAPE

3.1 The United States Food and Drug Administration

3.2 European Medicines Agency

3.3 Other Developments on the Biosimilar Front

3.3.1 The World Health Organization

3.3.2 Canada

3.3.3 Japan

3.3.4 Latin America

3.3.4.1 Argentina

3.3.4.2 Brazil

3.3.4.3 Mexico

3.3.5 India

4. KEY MARKET TRENDS

Biosimilars Growth to be Driven by Emerging Markets over the Next Decade

Asia Poised to Manufacturing Hub for Biosimilars

Biosimilars: Present Perspectives and Future Implications

Key Considerations for Biosimilars Development and Commercialization in the US

The FDA Guidelines

An Assessment of the Current and Future Trends Of Biosimilars in the United States and India

Biosimilars: Some Quick Facts

The United States Market for Biosimilars

The Indian Market for Biosimilars

Biosimilars could Drive-Down the Cost of Cancer Treatment

FDA Draft Guidance Triggers Evaluation of IP Protection

Biosimilar Therapeutics Showing 'Similarity'

Key Issues in Biosimilars Commercialization

Biosimilars in the US: Regulation, Strategies, and Impact

Oncologists Urged to Consider Biosimilars as Cost-Effective Treatment Options

Biosimilars Development: Opportunities and Challenges

Key Biosimilar Developments During 2011

Biosimilars Business Blooming in India

Prospects

Indian Initiatives…

Roadblocks Remain

Opportunities for Biosimilars in Emerging Markets

5. KEY GLOBAL PLAYERS

3SBio Inc

Actavis Group HF.

Agilent Technologies, Inc.

Amgen, Inc.

Astrazeneca Plc

Baxter International Inc.

Biocon Ltd.

Biogen IDEC

Bioton S.A.

Boehringer Ingelheim GmbH

Cadila Healthcare Limited

Cangene Corp.

Celltrion, Inc.

Cipla Ltd.

Daiichi Sankyo Company Limited

Dong-A Pharmaceutical Co., Ltd

Dr. Reddy's Laboratories Ltd.

DSM Biologics

GE Healthcare Ltd.

Glaxosmithkline, Plc

Hospira, Inc.

iBio, Inc.

LG Life Sciences

Lonza Group Ltd

Medice Arzneimittel Pütter GmbH & Co KG

Merck & Co., Inc.

Merck KGaA

Mitsubishi Tanabe Pharma Corporation

Mylan Inc.

Novartis AG

Perkinelmer, Inc.

Pfizer Inc

Ranbaxy Laboratories Ltd.

Reliance Life Sciences Pvt Ltd

Roche Holding AG

Samsung Biologics Co Ltd

Sandoz International GmbH

Sanofi

Shantha Biotechnics Ltd

Stada Arzneimittel AG

Teva Pharmaceutical Industries Ltd.

Watson Pharmaceuticals, Inc.

Wockhardt Limited

6. KEY BUSINESS TRENDS

ProCognia to expand biosimilar collaboration with UniTargeting Research

Oncobiologics, Boston Oncology to Commercialize Biosimilar Therapies in MENA region

Innovent Biologics Engages Pharmatech Associates for Designing Biosimilars Facility in China

Sandoz Initiates Phase-III Trial for Epoetin Alfa

AET BioTech, BioXpress Therapeutics Sign Deal for Cancer mAb

Reliance Life Sciences Starts Biosimilar Infliximab Trial in India

Fujifilm Kyowa Kirin Biologics to Develop Bevacizumab Biosimilar

Roche's Rituxan Biosimilar Copies in Market By 2015

Asian Biotech Companies to Pioneer Biosimilars for Renal Failure

Dr Reddy's Negotiating for Europe Reditux debut

FDA approves Teva Cancer Treatment Biosimilar

FDA Approves Teva's Tbo-filgrastim Version

iBio and GE Healthcare Announce Global Alliance

Synthon Strikes Deal for Developing Herceptin Biosimilar

Stakeholder Groups Urging FDA to Exempt Plasma Protein Therapy from Biosimilar Pathway

Ranbaxy to Commercialize Three Biosimilars by 2015

Korean FDA Approves Celltrion's First Monoclonal Antibody

Biocon Announces Positive Results for Biosimilar Insulin Glargine Phase I Trial

Dr Reddy's to Collaborate with Merck Serono on Biosimilars

India Announces New Regulations for Biosimilars

Abbott Challenging Provision in Federal Biosimilar Law

Amgen Endorses EMA Guidance on Biosimilar mAb

Finox Biotech Completes Phase III Trial of Biosimilar r-FSH

Court Rules against Merck in Nasonex Patent Infringement Case

PlantForm's Biosimilar Trastuzumab Equivalent to Brand Drug In Vivo

Daiichi Sankyo, Coherus BioSciences in Biosimilar Deal

Amgen, PRA in Biosimilars Deal

Pfizer Starts Biosimilar Rituximab Phase I/II trial

Daiichi Sankyo, Coherus Biosciences Collaborating to Commercialize Biosimilars

EMA Reviewing Biosimilar Version of Infliximab

Samsung to Launch Cheaper Biosimilars by 2015

Biocon Commences Advanced Research Centre in Bangalore

Amgen Seeking Clinical Trial Clarification on Biosimilars

Fujifilm, Kyowa in Joint Venture for Humira

Dr Reddy's Betting High on Biosimilars

GE Healthcare Acquires Xcellerex to Expand Biologicals Offering

Celerion, Ricerca in Biosimilar Alliance

Biocon and Pfizer Conclude Commercialization Agreement

Samsung Biologics and Biogen Idec from Biosimilars Joint Venture

Sandoz Initiates Phase III Trials for Filgrastim and Pegfilgrastim

Hospira begins US Phase III Trial for Biosimilar EPO

Mochida, Fuji Pharma File Biosimilar G-CSF in Japan

Transgene Moves rh-EPO Technology to German TSS Export

Momenta, Baxter in Biosimilar Alliance

Amgen Issued New US Patent on Enbrel

Biocon starts R&D Facility in Bio-XCell, Malaysia

Dong-A to Establish Biosimilar Plant in Songdo

iBio Produces Rituximab in Plants

Pharmerging Countries India and China Promising to Rollout Cheaper Biosimilars

Boehringer Ingelheim Ventures into Biosimilars

Sanofi Announces Fresh Long-Term Objectives

Hospira Looks to Biosimilars and Increased use of Generics for Growth

Stada, Richter to Collaborate on Biosimilar Development

IMS Launches MIDAS Biosimilars

Biosmilars Luring Unlikely Partnerships

Merck, Hanwha Ink Enbrel Deal

Lupin-NeuClone Deal to Develop Oncology Biosimilars

Brazil to Manufacture Biosimilar Adalimumab

Spectrum, Viropro to Develop Rituximab Biosimilar

Sandoz Monitoring Ongoing Biosimilar G-CSF (filgrastim) Study

South Korea to Promote Investments in Biosimilars

Sandoz Announces Start of Phase II Trial for Biosimilar Rituximab

Dr Reddy's Releases Biosimilar Aranesp

7. GLOBAL MARKET OVERVIEW

7.1 Market Overview by Application Area

7.1.1 Biosimilars Application Area Overview by Global Region

7.1.1.1 Blood Disorders

7.1.1.2 Chronic Diseases

7.1.1.3 Growth Hormone Deficiency

7.1.1.4 Oncology

7.1.1.5 Other Biosimilar Applications

7.2 Market Overview by Product Segment

7.2.1 Biosimilars Product Segment Overview by Global Region

7.2.1.1 Biosimilar Monoclonal Antibodies

7.2.1.2 Biosimilar Erythropoietin

7.2.1.3 Biosimilar Human Growth Hormone

7.2.1.4 Biosimilar Insulin

7.2.1.5 Biosimilar G-CSF

7.2.1.6 Biosimilar Interferons

7.2.1.7 Other Biosimilar Products

PART B: REGIONAL MARKET PERSPECTIVE

REGIONAL MARKET OVERVIEW

1. THE UNITED STATES

1.1 Market Overview by Application Area

1.2 Market Overview by Product Segment

1.3 Major Market Players

Agilent Technologies, Inc.

Amgen, Inc.

Baxter International Inc.

Biogen IDEC

Dynavax Technologies Corporation

Hospira, Inc.

iBio, Inc.

Merck & Co., Inc.

Momenta Pharmaceuticals inc

Mylan Inc.

Perkinelmer, Inc.

Pfizer Inc

Watson Pharmaceuticals, Inc.

2. EUROPE

2.1 Current Market Scenario

2.2 Market Overview by Geographic Region

2.3 Market Overview by Application Area

2.3.1 Biosimilars Application Area Overview by European Region

2.3.1.1 Blood Disorders

2.3.1.2 Chronic Diseases

2.3.1.3 Growth Hormone Deficiency

2.3.1.4 Oncology

2.3.1.5 Other Biosimilar Applications

2.4 Market Overview by Product Segment

2.4.1 Biosimilars Product Segment Overview by European Region

2.4.1.1 Biosimilar Monoclonal Antibodies

2.4.1.2 Biosimilar Erythropoietin

2.4.1.3 Biosimilar Human Growth Hormone

2.4.1.4 Biosimilar Insulin

2.4.1.5 Biosimilar G-CSF

2.4.1.6 Biosimilar Interferons

2.4.1.7 Other Biosimilar Products

2.5 Major Market Players

Actavis Group HF. (Iceland)

Astrazeneca PLC (United Kingdom)

BiogEnerix AG (Germany)

Biopartners GmbH (Switzerland)

Bioton S.A. (Poland)

Boehringer Ingelheim GmbH (Germany)

DSM Biologics (The Netherlands)

GE Healthcare Ltd. (United Kingdom)

Glaxosmithkline, PLC (United Kingdom)

Hexal AG (Germany)

Lonza Group Ltd (Switzerland)

Medice Arzneimittel Pütter GmbH & Co Kg (Germany)

Merck KGaA (Germany)

Novartis AG (Switzerland)

Roche Holding AG (Switzerland)

Sandoz International GmbH (Germany)

Sanofi (France)

Stada Arzneimittel AG (Germany)

2.6 European Market Overview by Country

2.6.1 France

2.6.1.1 Market Overview by Application Area

2.6.1.2 Market Overview by Product Segment

2.6.2 Germany

2.6.2.1 Market Overview by Application Area

2.6.2.2 Market Overview by Product Segment

2.6.3 Italy

2.6.3.1 Market Overview by Application Area

2.6.3.2 Market Overview by Product Segment

2.6.4 Spain

2.6.4.1 Market Overview by Application Area

2.6.4.2 Market Overview by Product Segment

2.6.5 United Kingdom

2.6.5.1 Market Overview by Application Area

2.6.5.2 Market Overview by Product Segment

2.6.6 Rest of Europe

2.6.6.1 Market Overview by Application Area

2.6.6.2 Market Overview by Product Segment

3. ASIA-PACIFIC

3.1 Market Overview by Geographic Region

3.2 Market Overview by Application Area

3.2.1 Biosimilars Application Area Overview by Asia-Pacific Region

3.2.1.1 Blood Disorders

3.2.1.2 Chronic Diseases

3.2.1.3 Growth Hormone Deficiency

3.2.1.4 Oncology

3.2.1.5 Other Biosimilar Applications

3.3 Market Overview by Product Segment

3.3.1 Biosimilars Product Segment Overview by Asia-Pacific Region

3.3.1.1 Biosimilar Monoclonal Antibodies

3.3.1.2 Biosimilar Erythropoietin

3.3.1.3 Biosimilar Human Growth Hormone

3.3.1.4 Biosimilar Insulin

3.3.1.5 Biosimilar G-CSF

3.3.1.6 Biosimilar Interferons

3.3.1.7 Other Biosimilar Products

3.4 Major Market Players

3SBio Inc (China)

Anhui Anke Biotechnology (Group) Co., Ltd. (China)

Bharat Biotech International Limited (India)

Biocon Ltd. (India)

Cadila Healthcare Limited (India)

Celltrion, Inc. (South Korea)

Cipla Ltd. (India)

Claris Lifesciences Limited (India)

Daiichi Sankyo Company Limited (Japan)

Dong-A Pharmaceutical Co., Ltd (South Korea)

Dr. Reddy's Laboratories Ltd. (India)

Intas Biopharmaceuticals Ltd. (India)

LG Life Sciences (South Korea)

Mitsubishi Tanabe Pharma Corporation (Japan)

Ranbaxy Laboratories Ltd. (India)

Reliance Life Sciences Pvt Ltd (India)

Samsung Biologics Co Ltd (South Korea)

Shantha Biotechnics Ltd (India)

Wockhardt Limited (India)

3.5 Asia-Pacific Market Overview by Country

3.5.1 China

3.5.1.1 Current Market Scenario

3.5.1.2 Market Overview by Application Area

3.5.1.3 Market Overview by Product Segment

3.5.2 India

3.5.2.1 Current Market Scenario

3.5.2.2 Market Overview by Application Area

3.5.2.3 Market Overview by Product Segment

3.5.3 South Korea

3.5.3.1 Current Market Scenario

3.5.3.2 Market Overview by Application Area

3.5.3.3 Market Overview by Product Segment

3.5.4 Rest of Asia-Pacific

3.5.4.1 Market Overview by Application Area

3.5.4.2 Market Overview by Product Segment

4. REST OF WORLD

4.1 Market Overview by Application Area

4.2 Market Overview by Product Segment

4.3 Major Market Players

Bioclones (Pty) Ltd. (South Africa)

Cangene Corp. (Canada)

Medicago Inc. (Canada)

Teva Pharmaceutical Industries Ltd. (Israel)

PART C: GUIDE TO THE INDUSTRY

1. NORTH AMERICA

1.1 Canada

1.2 United States

2. EUROPE

2.1 France

2.2 Germany

2.3 Hungary

2.4 Iceland

2.5 Ireland

2.6 Lithuania

2.7 Malta

2.8 Poland

2.9 Russia

2.10 Spain

2.11 Switzerland

2.12 The Netherlands

2.13 United Kingdom

3. ASIA-PACIFIC

3.1 Australia

3.2 China

3.3 India

3.4 Japan

3.5 Singapore

3.6 South Korea

3.7 Taiwan

3.8 Vietnam

4. REST OF WORLD

4.1 Brazil

4.2 Iran

4.3 Israel

4.4 Mexico

4.5 South Africa

PART D: ANNEXURE

1. RESEARCH METHODOLOGY

2. THE QUESTIONNAIRE

3. FEEDBACK

Charts & Graphs

PART A: GLOBAL MARKET PERSPECTIVE

Chart 1: The Leading mAbs and Years of Patent Expiry in United States and Europe

Chart 2: The Biosimilar Manufacturers with Most No. of mAbs in Pipeline

Chart 3: The Global Top-5 Biosimilar Manufacturers by Market Shares (%) for 2011 & 2012

Chart 4: Analysis of Global Biosimilars Market (2012 & 2015) for Application in Blood Disorders by Geographic Region

Chart 5: Analysis of Global Biosimilars Market (2012 & 2015) for Application in Chronic Diseases by Geographic Region

Chart 6: Analysis of Global Biosimilars Market (2012 & 2015) for Application in Growth Hormone Deficiencies by Geographic Region

Chart 7: Analysis of Global Biosimilars Market (2012 & 2015) for Application in Oncology by Geographic Region

Chart 8: A Comparative Study on Biosimilars Between The Approaches of The European Union and The United States

Chart 9: The Innovator Products and their Corresponding Biosimilars by Company

Chart 10: Global Biosimilars Market Analysis (2009-2018) in USD Million

Chart 11: Global Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million

Chart 12: Glance at 2009, 2013 and 2018 Global Biosimilars Market Share (%) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other

Chart 13: Glance at 2009, 2013 and 2018 Global Blood Disorders Market Share (%) of Biosimilars by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million

Chart 14: Glance at 2009, 2013 and 2018 Global Blood Disorders Market Share (%) of Biosimilars by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

Chart 15: Global Biosimilars Market Analysis (2009-2018) for Application in Chronic Diseases by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million

Chart 16: Glance at 2009, 2013 and 2018 Global Chronic Diseases Market Share (%) of Biosimilars by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

Chart 17: Global Biosimilars Market Analysis (2009-2018) for Application in Growth Hormone Deficiency by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million

Chart 18: Glance at 2009, 2013 and 2018 Global Growth Hormone Deficiency Market Share (%) of Biosimilars by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

Chart 19: Global Biosimilars Market Analysis (2009-2018) for Application in Oncology by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million

Chart 20: Glance at 2009, 2013 and 2018 Global Oncology Market Share (%) of Biosimilars by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

Chart 21: Global Biosimilars Market Analysis (2009-2018) for Other Applications by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million

Chart 22: Glance at 2009, 2013 and 2018 Global Other Biosimilar Applications Market Share (%) of Biosimilars by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

Chart 23: Global Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million

Chart 24: Glance at 2009, 2013 and 2018 Global Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other

Chart 25: Global Biosimilar Monoclonal Antibodies Market Analysis (2009-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million

Chart 26: Glance at 2009, 2013 and 2018 Global Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

Chart 27: Global Biosimilar Erythropoietin Market Analysis (2009-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million

Chart 28: Glance at 2009, 2013 and 2018 Global Biosimilar Erythropoietin Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

Chart 29: Global Biosimilar Human Growth Hormone Market Analysis (2009-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million

Chart 30: Glance at 2009, 2013 and 2018 Global Biosimilar Human Growth Hormone Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

Chart 31: Global Biosimilar Insulin Market Analysis (2009-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million

Chart 32: Glance at 2009, 2013 and 2018 Global Biosimilar Insulin Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

Chart 33: Global Biosimilar G-CSF Market Analysis (2009-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million

Chart 34: Glance at 2009, 2013 and 2018 Global Biosimilar G-CSF Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

Chart 35: Global Biosimilar Interferons Market Analysis (2009-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million

Chart 36: Glance at 2009, 2013 and 2018 Global Biosimilar Interferons Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

Chart 37: Global Other Biosimilar Products Market Analysis (2009-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million

Chart 38: Glance at 2009, 2013 and 2018 Global Other Biosimilar Products Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

PART B: REGIONAL MARKET PERSPECTIVE

Chart 39: The Projection of Largest Regions in terms of Market Growth (2009-2018) for Biosimilars by Geography – United States, Europe and Asia-Pacific

Chart 40: Global Biosimilars Market Analysis (2009-2018) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World in USD Million

Chart 41: Glance at 2009, 2013 and 2018 Global Biosimilars Market Share (%) by Geographic Region – United States, Europe, Asia-Pacific and Rest of World

THE UNITED STATES

Chart 42: United States Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million

Chart 43: Glance at 2009, 2013 and 2018 United States Biosimilars Market Share (%) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other

Chart 44: United States Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million

Chart 45: Glance at 2009, 2013 and 2018 United States Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other

EUROPE

Chart 46: European Biosimilars Market Analysis (2009-2018) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million

Chart 47: Glance at 2009, 2013 and 2018 European Biosimilars Market Share (%) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe

Chart 48: European Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million

Chart 49: Glance at 2009, 2013 and 2018 European Biosimilars Market Share (%) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other

Chart 50: European Biosimilars Market Analysis (2009-2018) for Application in Blood Disorders by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million

Chart 51: Glance at 2009, 2013 and 2018 European Blood Disorders Market Share (%) of Biosimilars by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe

Chart 52: European Biosimilars Market Analysis (2009-2018) for Application in Chronic Diseases by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million

Chart 53: Glance at 2009, 2013 and 2018 European Chronic Diseases Market Share (%) of Biosimilars by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe

Chart 54: European Biosimilars Market Analysis (2009-2018) for Application in Growth Hormone Deficiency by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million

Chart 55: Glance at 2009, 2013 and 2018 European Growth Hormone Deficiency Market Share (%) of Biosimilars by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe

Chart 56: European Biosimilars Market Analysis (2009-2018) for Application in Oncology by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million

Chart 57: Glance at 2009, 2013 and 2018 European Oncology Market Share (%) of Biosimilars by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe

Chart 58: European Biosimilars Market Analysis (2009-2018) for Other Applications by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million

Chart 59: Glance at 2009, 2013 and 2018 European Other Biosimilar Applications Market Share (%) of Biosimilars by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe

Chart 60: European Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million

Chart 61: Glance at 2009, 2013 and 2018 European Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other

Chart 62: European Biosimilar Monoclonal Antibodies Market Analysis (2009-2018) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million

Chart 63: Glance at 2009, 2013 and 2018 European Biosimilar Monoclonal Antibodies Market Share (%) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe

Chart 64: European Biosimilar Erythropoietin Market Analysis (2009-2018) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million

Chart 65: Glance at 2009, 2013 and 2018 European Biosimilar Erythropoietin Market Share (%) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe

Chart 66: European Biosimilar Human Growth Hormone Market Analysis (2009-2018) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million

Chart 67: Glance at 2009, 2013 and 2018 European Biosimilar Human Growth Hormone Market Share (%) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe

Chart 68: European Biosimilar Insulin Market Analysis (2009-2018) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million

Chart 69: Glance at 2009, 2013 and 2018 European Biosimilar Insulin Market Share (%) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe

Chart 70: European Biosimilar G-CSF Market Analysis (2009-2018) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million

Chart 71: Glance at 2009, 2013 and 2018 European Biosimilar G-CSF Market Share (%) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe

Chart 72: European Biosimilar Interferons Market Analysis (2009-2018) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million

Chart 73: Glance at 2009, 2013 and 2018 European Biosimilar Interferons Market Share (%) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe

Chart 74: European Other Biosimilar Products Market Analysis (2009-2018) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe in USD Million

Chart 75: Glance at 2009, 2013 and 2018 European Other Biosimilar Products Market Share (%) by Geographic Region – France, Germany, Italy, Spain, United Kingdom and Rest of Europe

France

Chart 76: French Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million

Chart 77: Glance at 2009, 2013 and 2018 French Biosimilars Market Share (%) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other

Chart 78: French Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million

Chart 79: Glance at 2009, 2013 and 2018 French Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other

Germany

Chart 80: German Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million

Chart 81: Glance at 2009, 2013 and 2018 German Biosimilars Market Share (%) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other

Chart 82: German Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million

Chart 83: Glance at 2009, 2013 and 2018 German Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other

Italy

Chart 84: Italian Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million

Chart 85: Glance at 2009, 2013 and 2018 Italian Biosimilars Market Share (%) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other

Chart 86: Italian Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million

Chart 87: Glance at 2009, 2013 and 2018 Italian Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other

Spain

Chart 88: Spanish Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million

Chart 89: Glance at 2009, 2013 and 2018 Spanish Biosimilars Market Share (%) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other

Chart 90: Spanish Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million

Chart 91: Glance at 2009, 2013 and 2018 Spanish Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other

United Kingdom

Chart 92: United Kingdom Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million

Chart 93: Glance at 2009, 2013 and 2018 United Kingdom Biosimilars Market Share (%) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other

Chart 94: United Kingdom Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million

Chart 95: Glance at 2009, 2013 and 2018 United Kingdom Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other

Rest of Europe

Chart 96: Rest of Europe Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million

Chart 97: Glance at 2009, 2013 and 2018 Rest of Europe Biosimilars Market Share (%) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other

Chart 98: Rest of Europe Biosimilars Market Analysis (2009-2018) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other in USD Million

Chart 99: Glance at 2009, 2013 and 2018 Rest of Europe Biosimilars Market Share (%) by Product Segment – Monoclonal Antibodies, Erythropoietin, Human Growth Hormone, Insulin, G-CSF, Interferons and Other

ASIA-PACIFIC

Chart 100: Asia-Pacific Biosimilars Market Analysis (2009-2018) by Geographic Region – China, India, South Korea and Rest of Asia-Pacific in USD Million

Chart 101: Glance at 2009, 2013 and 2018 Asia-Pacific Biosimilars Market Share (%) by Geographic Region – China, India, South Korea and Rest of Asia-Pacific

Chart 102: Asia-Pacific Biosimilars Market Analysis (2009-2018) by Application Area – Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Oncology and Other in USD Million

Chart 103: Glance at 2009, 2013 and 2018 Asia-Pacific Biosimilars Market Share (%) by Application Area – Bloo

To order this report:

Generic_Drug Industry: Global Biosimilars Market - Products, Applications and Regulations

Contact Nicolas: nicolasbombourg@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Copyright 2012 PR Newswire



Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 in 141127 19:47